In this issue:
TNF-α antagonists and cancer risk
Optimal bowel preparation for colonoscopy
Anti-TNF-α antibodies and mucosal healing in IBD
The microbiome in new-onset CD
Treatment algorithm for adalimumab
Methotrexate plus infliximab in CD
Early corticosteroids predict long-term UC course
Adalimumab induced deep remission in CD
Certolizumab pegol and endoscopic CD outcomes
Barriers to mesalamine adherence
UC risk in a North Indian population
Science Blog: Role of NOD2 in the pathogenesis of CD
Please login below to download this issue (PDF)